MA49705A - Intermédiaires utiles pour la synthèse d'un inhibiteur sélectif vis-à-vis de la protéine kinase et leurs procédés de préparation - Google Patents

Intermédiaires utiles pour la synthèse d'un inhibiteur sélectif vis-à-vis de la protéine kinase et leurs procédés de préparation

Info

Publication number
MA49705A
MA49705A MA049705A MA49705A MA49705A MA 49705 A MA49705 A MA 49705A MA 049705 A MA049705 A MA 049705A MA 49705 A MA49705 A MA 49705A MA 49705 A MA49705 A MA 49705A
Authority
MA
Morocco
Prior art keywords
synthesis
protein kinase
kinase inhibitor
preparation processes
selective protein
Prior art date
Application number
MA049705A
Other languages
English (en)
Inventor
Sang-Seol Jeon
Hyun Ju
Ja-Heouk Khoo
Doo-Byung Lee
Jun-Sup Lee
Jung-Ae Lee
Jong-Chul Lim
Sang-Ho Oh
Woo-Seob Shin
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65040643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49705(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MA49705A publication Critical patent/MA49705A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
MA049705A 2017-07-28 2018-07-25 Intermédiaires utiles pour la synthèse d'un inhibiteur sélectif vis-à-vis de la protéine kinase et leurs procédés de préparation MA49705A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20170096226 2017-07-28

Publications (1)

Publication Number Publication Date
MA49705A true MA49705A (fr) 2021-03-31

Family

ID=65040643

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049705A MA49705A (fr) 2017-07-28 2018-07-25 Intermédiaires utiles pour la synthèse d'un inhibiteur sélectif vis-à-vis de la protéine kinase et leurs procédés de préparation

Country Status (30)

Country Link
US (1) US11198684B2 (fr)
EP (1) EP3658547B1 (fr)
JP (1) JP7189932B2 (fr)
KR (2) KR102671396B1 (fr)
CN (1) CN111295381A (fr)
AU (1) AU2018308164B2 (fr)
CA (1) CA3070070A1 (fr)
CO (1) CO2020000371A2 (fr)
DK (1) DK3658547T3 (fr)
EA (1) EA038078B1 (fr)
ES (1) ES2959967T3 (fr)
FI (1) FI3658547T3 (fr)
HR (1) HRP20231020T1 (fr)
HU (1) HUE063043T2 (fr)
IL (1) IL271975B (fr)
LT (1) LT3658547T (fr)
MA (1) MA49705A (fr)
MX (1) MX393368B (fr)
MY (1) MY201038A (fr)
NZ (1) NZ761158A (fr)
PH (1) PH12020500093A1 (fr)
PL (1) PL3658547T3 (fr)
PT (1) PT3658547T (fr)
RS (1) RS64545B1 (fr)
SA (1) SA520411115B1 (fr)
SG (1) SG11201913556SA (fr)
SI (1) SI3658547T1 (fr)
SM (1) SMT202300297T1 (fr)
UA (1) UA125595C2 (fr)
WO (1) WO2019022487A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3658553T3 (da) * 2017-07-28 2022-07-25 Yuhan Corp Mellemprodukter som er anvendelige til syntesen af aminopyrimidinderivater, fremgangsmåde til fremstilling deraf og fremgangsmåde til fremstilling af aminopyrimidinderivater under anvendelse deraf
MX393995B (es) * 2017-07-28 2025-03-24 Yuhan Corp Proceso mejorado para preparar derivados de aminopirimidina
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
JOP20220184A1 (ar) 2020-02-12 2023-01-30 Janssen Biotech Inc علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
TW202207940A (zh) 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
WO2025052273A1 (fr) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Méthodes pour traiter le cancer du poumon non à petites cellules
WO2026042017A1 (fr) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab en association avec le lazertinib pour le traitement du cancer du poumon non à petites cellules (cpnpc)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201510696RA (en) * 2008-06-27 2016-01-28 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
JP5740409B2 (ja) * 2009-11-13 2015-06-24 ジェノスコ キナーゼ阻害剤
EP2736895B1 (fr) 2011-07-27 2016-01-06 Astrazeneca AB Deruves de 2-(2,4,5-substituted-anilino) pyrimidine comme modulatuers du egfr utiles dans le traitement du cancer
WO2013096642A1 (fr) 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
NZ627113A (en) * 2012-01-20 2016-07-29 Genosco Substituted pyrimidine compounds and their use as syk inhibitors
EP3144292B1 (fr) * 2014-04-14 2020-08-26 Shanghai Haiyan Pharmaceutical Technology Co., Ltd Dérivés de benzène-1,5-diamine 2,3,4,6-tétra-substitués, procédé de préparation associé et utilisation médicinale de ceux-ci
CN105461695B (zh) * 2014-09-29 2018-03-27 齐鲁制药有限公司 嘧啶或三嗪衍生物及其制备方法和用途
CN105524068B (zh) * 2014-09-30 2017-11-24 上海海雁医药科技有限公司 氮杂双环衍生物、其制法与医药上的用途
MX2017003181A (es) * 2014-10-13 2017-07-20 Yuhan Corp Compuestos y composiciones para modular actividades de quinasa de mutante de receptor del factor de crecimiento epidermico.
CN105859721B (zh) * 2015-01-22 2018-04-17 浙江京新药业股份有限公司 一种伊布鲁替尼的制备方法
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
EP3399968B8 (fr) * 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Inhibiteurs sélectifs de mutants cliniquement importants de la tyrosine kinase de l'egfr
CN106083736A (zh) * 2016-06-21 2016-11-09 郑州泰基鸿诺医药股份有限公司 一种嘧啶类化合物、egfr抑制剂及其应用

Also Published As

Publication number Publication date
SA520411115B1 (ar) 2023-01-18
KR102671396B1 (ko) 2024-05-31
EP3658547B1 (fr) 2023-08-16
RS64545B1 (sr) 2023-09-29
PL3658547T3 (pl) 2024-01-03
BR112020001457A2 (pt) 2020-07-28
EA038078B1 (ru) 2021-07-02
CN111295381A (zh) 2020-06-16
EA202090384A1 (ru) 2020-05-20
IL271975B (en) 2022-08-01
AU2018308164A1 (en) 2020-01-30
KR20190013555A (ko) 2019-02-11
SI3658547T1 (sl) 2023-10-30
AU2018308164B2 (en) 2021-12-09
UA125595C2 (uk) 2022-04-27
JP2020528916A (ja) 2020-10-01
CA3070070A1 (fr) 2019-01-31
JP7189932B2 (ja) 2022-12-14
SG11201913556SA (en) 2020-02-27
US11198684B2 (en) 2021-12-14
NZ761158A (en) 2022-08-26
KR20230137282A (ko) 2023-10-04
EP3658547A1 (fr) 2020-06-03
HRP20231020T1 (hr) 2023-12-08
EP3658547A4 (fr) 2021-03-31
WO2019022487A1 (fr) 2019-01-31
LT3658547T (lt) 2023-10-10
HUE063043T2 (hu) 2023-12-28
DK3658547T3 (da) 2023-10-16
PT3658547T (pt) 2023-10-20
KR102746929B1 (ko) 2024-12-26
FI3658547T3 (fi) 2023-10-26
PH12020500093A1 (en) 2020-09-14
US20210155607A1 (en) 2021-05-27
IL271975A (en) 2020-02-27
ES2959967T3 (es) 2024-02-29
CO2020000371A2 (es) 2020-05-05
SMT202300297T1 (it) 2023-11-13
MY201038A (en) 2024-01-31
MX393368B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
EP3658547A4 (fr) Intermédiaires utiles pour la synthèse d'un inhibiteur sélectif vis-à-vis de la protéine kinase et leurs procédés de préparation
MA48779A (fr) Formes cristallines d'inhibiteur de fgfr et leurs procédés de préparation
EP3709973A4 (fr) Procédés de production d'exosomes dérivés de csm
EP3684821A4 (fr) Anticorps anti-hla-a2 et leurs procédés d'utilisation
EP3645741A4 (fr) Anticorps anti-4-1bb et leurs procédés de préparation et d'utilisation
EP3774709A4 (fr) Procédés de réduction de l'inflammation du système digestif à l'aide d'inhibiteurs de hif-2-alpha
EP3504196A4 (fr) Procédés de préparation d'olaparib
MA47691A (fr) Anticorps anti-cd33 et leurs procédés d'utilisation
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
MA71266A (fr) Procédés d'intervention précoce pour prévenir ou améliorer la toxicité
EP3515880A4 (fr) Procédés et compositions pour la synthèse de bibliothèques codées
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
EP3694533A4 (fr) Procédés et compositions pour l'expansion de la population cellulaire
EP4009778A4 (fr) Procédés et compositions pour la production de mycéliums ectomycorhiziens et leurs procédés d'utilisation
EP3893655A4 (fr) Procédés pour la préparation d'un composition de protéines végétales
MA53445A (fr) Procédés et compositions pour la modification de plantes
MA45154A (fr) Procédés de préparation d'oligomères
MA53391A (fr) Compositions pour l'agriculture et procédés associés
EP3606929A4 (fr) Nucléotides d'ester de bêta-nicotinate et leurs procédés de préparation
EP3630046A4 (fr) Anticorps anti-doublecortin-like kinase 1 et leurs procédés d'utilisation
EP3582773A4 (fr) Procédés de préparation d'ag-10, de ses intermédiaires et de sels correspondants
EP3897717A4 (fr) Procédés de production d'anticorps hétérodimères
EP3645529A4 (fr) Procédé pour la préparation de lifitegrast et d'intermédiaires de celui-ci
EP3452084A4 (fr) Anticorps anti-kv 1.3 et procédés pour les produire et les utiliser
MA50516A (fr) Anticorps anti-apoc3 et leurs procédés d'utilisation